TABLE 3.
Etest fluconazole and voriconazole MICs for 66 non-WT (mutant) Candida spp. isolates and ECVsa
| Speciesb (no. of mutants) | FLU MICs | Etest ECV | VOR MIC | Etest ECVs | ERG point mutation(s)c |
|---|---|---|---|---|---|
| C. albicans (6) | 8 | 1 | 2 | 0.03 | A114S, G464S |
| >128 | 1 | 11 T220L, E266D, 448R | |||
| 32 | 0.25 | 11 Y132H, T220L, V437I | |||
| NG | 0.5 | 11 F145T, T220L, V437I | |||
| 4 | 0.5 | Y132F | |||
| 64 | 1 | CDR2/MDR overexpression | |||
| C. glabrata (5) | 128 | 128 | 2 | 1 | A114S, G464S |
| 128 | 4 | A114S, G464S | |||
| 128 | 4 | A114S, G464S | |||
| 128 | >8 | A114S, G464S | |||
| 128 | >8 | A114S, G464S | |||
| C. guilliermondii (2) | 16 | 16 | 0.25 | 0.5 | A114S, G464S |
| 16 | 1 | A114S, G464S | |||
| C. krusei (2) | 64 | 16 | >8 | 1 | Y87X |
| 32 | 4 | Y87X | |||
| C. parapsilosis (45) | 4(2) | 2 | 0.25 | 0.25 | Y132F |
| 8(26) | ND | Y132F | |||
| 16(11) | 0.25 | Y132F | |||
| 32 | 0.25 | A114S, G464S | |||
| 32 | 0.5 | Y132F | |||
| 32 | 0.25 | Y132F | |||
| 32 | 0.25 | Y132F | |||
| 64 | 1 | Y132F | |||
| >64 | 0.25 | Y132F | |||
| C. tropicalis (6) | >128 | 4 | 2 | 0.25 | K143R |
| >128 | 1 | K143R | |||
| >128 | 1 | K143R | |||
| >128 | 2 | Y132F | |||
| >128 | >32 | Y132F | |||
| >128 | >32 | G464D |
a
Calculated ECVs/ECOFFS (epidemiological cutoff values) based on MICs determined by the commercial bioMérieux Etest method (13). Posaconacole data were not included, only three ECVs were defined. FLU, fluconazole; VOR, voriconazole.
b
C. guilliermondii (Meyerozyma guilliermondii), C. krusei (Pichia kudriavzevii).